[Intervention with clarithromycin in patients with stable coronary heart disease--the CLARICOR trial: secondary publication].
Antibiotics may reduce cardiovascular morbidity. We randomised 4372 patients with stable coronary heart disease in the CLARICOR trial to clarithromycin 500 mg (n = 2172) or placebo (n = 2200) daily for a fortnight. After 2.6 years we found significantly increased cardiovascular mortality among the clarithromycin patients. There is a need for studies to evaluate the safety of clarithromycin. There is presently no evidence to support the preventive effect of antibiotics on patients with coronary heart disease.